FULGENT GENETICS, INC. Fair Value Inputs, Discount for Lack of Marketability (Deprecated 2018-01-31)
FULGENT GENETICS, INC. (FLGT) reported Fair Value Inputs, Discount for Lack of Marketability (Deprecated 2018-01-31) of 20.00% for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-20.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueInputsDiscountForLackOfMarketability · last filed 2018-03-20
- FULGENT GENETICS, INC. fair value inputs, discount for lack of marketability (deprecated 2018-01-31) for fiscal 2017 was 20.00%.
| Period end | Fair Value Inputs, Discount for Lack of Marketability (Deprecated 2018-01-31) 12 month |
|---|---|
| 2017-12-31 | 20.00% 10-K · filed 2018-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |